Xcout Intel
Imvax, Inc.
Imvax, Inc. is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing personalized, whole-cell immunotherapies for the treatment of various cancers.
Subscribe to see Imvax, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Imvax, Inc. at a glance
Imvax, Inc. is a biotechnology company headquartered in United States. It has raised at least $181.1M across the 4 funding rounds on record. Its most recent funding round, Series C, raised $29M in January 2025. Xcout tracks 9 named people at Imvax, Inc., including Sean P. Hemingway (Chief Operating Officer).
Imvax, Inc. leadership
- Sean P. HemingwayChief Operating Officer
- John M. LimongelliChief Financial Officer and Chief Legal Officer
- John P. FureyExecutive Chairman of the Board
- Peter B. CorrImvax Co-Founder; Auven Therapeutics Management LLP
- Ira BrindPresident, Brind Investments, Inc.
- David G. BunningTLP Investment Partners LLC
3 more named people on record for Imvax, Inc., with roles, board committees and tenure — see the full roster →
Imvax, Inc. funding rounds
At least $181.1M raised across the 4 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $29M | 4 named | |
| — | $112.4M | 5 named | |
| SEC Form D filing | $24.8M | — | |
| Series A | $15M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Imvax, Inc. competitors
A few of Imvax, Inc.'s closest competitors — see the full list of competitors and alternatives →
ImmunityBio, Inc. is a public clinical-stage immunotherapy company headquartered in San Diego, California. As a member of the NantWorks ecosystem, it focuses on developing next-generation cancer vaccines and immunotherapies.
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
IO Biotech, Inc. is a clinical-stage biopharmaceutical company that develops novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines. Its proprietary T-win® technology is designed to modulate the tumor microenvironment by targeting both tumor cells and immune-suppressive cells, aiming to improve treatment outcomes for patients with melanoma and other tumor types.
CancerVAX, Inc. is an American biotechnology and pharmaceutical company based in Lehi, Utah, founded in 2021. The company focuses on developing a breakthrough universal cancer treatment platform designed to disguise cancer cells.
Carisma Therapeutics is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on discovering and developing engineered macrophage-based immunotherapies.
Arcellx, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, dedicated to developing innovative immunotherapies and cell therapies for cancer patients.
Get Imvax, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Imvax, Inc. in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access